• On 27 June 2026, Syndax Pharmaceuticals, Inc. was removed from several Russell value benchmarks, including the Russell 2000 Value, 2500 Value, 3000 Value, and 3000E Value indexes.
• This broad index removal can meaningfully affect how index-linked investors and benchmark-focused funds treat the stock, potentially altering liquidity and ownership patterns.
• Next, we'll examine how Syndax's removal from multiple Russell value benchmarks could influence its existing investment narrative and risk profile.

This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.

Syndax Pharmaceuticals Investment Narrative Recap

To own Syndax today, you need to believe that Revuforj and Niktimvo can translate their clinical and regulatory momentum into durable commercial franchises, despite ongoing losses. The broad removal from multiple Russell value benchmarks may change who owns the stock and near term trading behavior, but it does not directly affect the key clinical and regulatory milestones or the central risk that setbacks for these two drugs could disproportionately weigh on the business.

In this context, the recent publication of SAVE trial data for the all oral Revuforj based regimen in relapsed or refractory AML looks especially important. The strong response rates and additional real world and frontline data being shared at EHA and ASCO speak directly to the core catalyst of expanding Revuforj’s role in AML treatment, which remains central to Syndax’s story regardless of how index reshuffling affects the shareholder base.

Yet despite this progress, investors still need to consider the possibility that heavier R&D spending and reimbursement pressures could...

Syndax Pharmaceuticals' narrative projects $748.0 million revenue and $110.2 million earnings by 2029. This requires 63.1% yearly revenue growth and a $395.6 million earnings increase from -$285.4 million today.

Uncover how Syndax Pharmaceuticals' forecasts yield a $39.50 fair value, a 85% upside to its current price.

Exploring Other Perspectives

While index removal raises fresh questions about liquidity and sentiment, the most optimistic analysts were recently forecasting US$942,100,000 revenue and US$182,700,000 earnings by 2029, highlighting how far opinions can diverge and why it is worth weighing several views before deciding how this latest news might reshape expectations.

Explore 5 other fair value estimates on Syndax Pharmaceuticals - why the stock might be worth over 6x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Syndax Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Syndax Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Syndax Pharmaceuticals' overall financial health at a glance.

Looking For Alternative Opportunities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 44 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.